---
title: Bipolar H.A Versus Trochanteric Antegrade Nail for Treatment of Displaced Subcapital Femoral Fractures
nct_id: NCT01181037
overall_status: UNKNOWN
sponsor: Meir Medical Center
study_type: OBSERVATIONAL
primary_condition: Displaced Subcapital Femoral Fracture
countries: Israel
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01181037.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01181037"
ct_last_update_post_date: 2012-03-19
last_seen_at: "2026-05-12T07:12:17.985Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Bipolar H.A Versus Trochanteric Antegrade Nail for Treatment of Displaced Subcapital Femoral Fractures

**NCT ID:** [NCT01181037](https://clinicaltrials.gov/study/NCT01181037)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 200
- **Lead Sponsor:** Meir Medical Center
- **Conditions:** Displaced Subcapital Femoral Fracture
- **Start Date:** 2010-06
- **Completion Date:** 2012-04
- **CT.gov Last Update:** 2012-03-19

## Brief Summary

A retrospective study to compare clinical results of patients that were treated by Bipolar H.A. vs. closed reduction and internal fixation with Trochanteric Antegrade Nail for displaced femoral subcapital fracture.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 85 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Displaced femoral subcapital fracture.
* Active patient.
* Age 40-85.
* Patient was treated by one of the two methods.

Exclusion Criteria:

* Age out of range.
```

## Arms

- **100 patients, displaced subcapital fracture, T.A.N nail.** — 100 patients sustained a displaced femoral subcapital fracture, that were operated on with closed reduction and internal fixation with TAN nail.
- **100 patients, displaced subcapital fracture, Bipolar H.A..**

## Primary Outcomes

- **describe treatment of patients that were treated by Bipolar H.A. vs. closed reduction and internal fixation** _(time frame: 6month to 3 years following operation)_ — A retrospective study will defer between groups

## Locations (1)

- Meir Medical Center, Kfar Saba, Israel, Israel — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.meir medical center|kfar saba|israel|israel` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01181037.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01181037*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*